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Lipopolysaccharide (LPS), a major component of the outer membranes of gram (-) bacteria, is released during infection and induces a number of pathological reactions leading to cardiovascular failure and damage to numerous organs. LPS can elicit a systemic inflammatory response syndrome defined as sepsis. When sepsis is accompanied by hypotension plus organ dysfunction, the condition is known as septic shock and the mortality of animals in septic shock has remained high. The common mechanism of tissues damage in the septic shock may be related to widespread vascular endothelial injury and microthrombosis. Homeostasis fails and dysfunction of major organs (heart, kidney, liver) may occur (Hardaway 2000 ; Ca den as and Ca d en a s 2002).
There is convincing evidence of severe oxidative stress in sepsis. Oxidative stress occurs when antioxidant balance is disrupted by excessive production of reactive oxygen species (ROS) such as superoxide radical, hydroxyl radical, hydrogen peroxide, singlet oxygen and/or by inadequate antioxidant defense mechanisms such as superoxide dismutase (SOD) and glutathione peroxidase (GPX) may occur in sepsis (Macdonald et al. 2003 ). ROS constitute a major part of biologically important free radicals (Toyokuni 1999; Suzzocrea et al. 2001 ). There is a large amount of evidence to show that the production of ROS occurs at the site of inflammation/infection and contributes to tissue damage (Cnubben et al. 2001; Suzzocrea et al. 2001 ) and current knowledge indicates that free radical damage plays a key role in LPS-induced septic shock (Ben-Shaul et al. 2001; Cadenas and Cadenas 2002) . Recently, a potential role of superoxide radical in septic shock has been identified (Salvemini and Cuzzocrea 2002) .
Oxidative stress can be prevented by the action of enzymatic and chemical antioxidant defenses in the body. The enzyme that provides the first line of defense against ROS damage (Cnubben et al. 2001) . SOD catalyses two molecules of superoxide to hydrogen peroxide and molecular oxygen, however, it is source of cellular hydrogen peroxide (Nordberg and Arner 2001) . GPX plays a critical role in the defense against oxidative stress (Dringen 2000; Cnubben et al. 2001) , it catalyses the reduction of hydrogen peroxide or lipid peroxides with reduced glutathione (GSH) (Chan and Decker 1994) . When antioxidant capacity is not sufficient against to ROS, lipid peroxidation occurs in the cell. Malondialdehyde (MDA) is formed during the lipid peroxidation (Valenzuela 1991) and it is accepted as a marker of lipid peroxidation (Macdonald et al. 2003) .
Pentoxifylline (PTX) is a phosphodiesterase inhibitor that inhibits TNFα release and neurophil adhesiveness and degranulation. In endotoxemic animal, PTX improves tissue oxygen extraction capabilities (Vincent 1997; Hanna 2003) . It is stated that PTX may be beneficial in endotoxemia (Krysztopik et al. 2000) .
In the present study, SOD and GPX activities were measured as antioxidant enzymes, MDA was measured as a marker of lipid peroxidation and GSH was determined as well in the heart, liver and kidney. Liver was selected because it is one of the tissues showing a high rate of free radical generation, and the kidney is the body's most important organ of excretion and homeostasis and it is a frequent target for a variety of toxic agents due to its metabolic capacity for concentrating toxicants and/or metabolites during the excretory process (Pfaller et al. 1990; Perez-Campo et al. 1993) . Heart is the main organ of circulatory system and depressed by β-endorphins in shock (Kaya 1997) . The aim of this study was to investigate the possible protective effect of pentoxifylline as on antioxidant status in healthy and endotoxemic New Zealand white rabbits.
Materials and Methods
The study was carried out on 40 male New Zealand white rabbits aged 8-10 months and weighing 2-2.5 kg. The animals were reared at Selcuk University Experimental Medicine Research and Application Centre (Konya, Turkey). Animals were fed standard pellet diet and tap water ad libitum. Ethical Committee of the Faculty of Veterinary Medicine (report No. 2004/03) approved the study protocol. . Study groups were formed as follows:
Group 1: control with no treatment Group 2: the animals were injected LPS (400 µg/kg) intravenously (Escherichia coli LPS 0111;B4, Sigma, auricular vein).
Group 3: the animals were injected PTX (50 mg/kg) intraperitoneally (Trental ® amp, Hoechst Marion Roussel, Istanbul, Turkey).
Group 4: the animals were injected PTX (50 mg/kg, intraperitoneally) and LPS (400 µg/kg, intravenously) simultaneously.
All rabbits were killed (Nembutal, 60 mg·kg -1 i.v.) and tissue samples (liver, heart and kidney) were collected at 6 hours after treatments. Samples were stored -80 °C until analyses.
MDA (Mihara and Uchiyama 1978) and GSH (Ellman 1959) levels of tissues were determined by previously reported spectrometric (Shimadzu UV-1601, Japan) methods. SOD (Randox-Ransod, 125), GPX (Randox-Ransel, 505) and total protein level (Sigma) were measured commercially available kits with spectrophotometer.
All values are expressed as mean ± SE. The results were analyzed by Tukey multiple range test (SPSS for windows, release 6.0). In all cases, probability of error of less than 0.05 was selected as the criterion for statistical significance.
Results and Discussion
Effect of pentoxifylline on malondialdehyde, superoxide dismutase, glutathione peroxidase and reduced glutathione levels of tissues in healthy and endotoxemic New Zealand rabbits is given in Table 1 .
Studies reported so far that were related to effect of LPS on antioxidant status yielded controversial results. In the present study, LPS increased hepatic MDA, and cardiac, hepatic and renal GPX levels. On the other hand, it decreased hepatic SOD activity. It was stated that LPS increased MDA levels of heart, plasma (Ben-Shaul et al. 2001; Altavilla et al. 2002 ), brain (Kheir-Eldin et al. 2001 Abd El-Gawad and Khalifa 2001) and diaphragm (Arias-Diaz et al. 1997) . In addition to these, it was reported that LPS increased GPX activity of brain (Abd El-Gawad and Khalifa 2001) and decreased SOD activity of macrophages (Joe and Lokesh 1997) . These data are agreement with our results. On the contrary, it was reported that LPS increased hepatic Mn-SOD (Portoles et al. 1996) , cardiac SOD activities (Ben-Shaul et al. 2001) , and decreased GPX activity of hepatocytes (Catala and Portoles 2002) .
In PTX-treated group, PTX caused significant increases of MDA levels in liver and heart, GSH levels of all tissue samples, SOD activity of heart and GPX activity of kidney when compared to control group. On the other hand, when LPS and PTX were administered simultaneously, PTX had no protective antioxidant effect. In this study, LPS+PTX increased MDA and GSH levels of all tissues, and renal SOD and GPX activities, and hepatic GPX activity. It was reported that PTX increased liver MDA, SOD, GPX levels in ischemia/reperfusion (Demir and Inal-Erden 1998) . Contrary to this result, it was reported that LPS increased MDA level of diaphragm and PTX prevented this increases (Arias-Diaz et al. 1997) , and PTX decreased tissue MDA levels in rats after skin ulceration induced by adriamycin (Bekerecioglu et al. 1998) . It was stated that PTX might be beneficial in endotoxaemia (Krysztopik et al. 2000) and PTX increased the survival time in severe endotoxaemia of rats (W u et al. 1999 ). However, it was stated that PTX did not have significant antioxidant capacity at therapeutic concentrations, but increasing their concentrations led to a significant scavenger effect in humans (Horvath et al. 2002) . As a result, PTX may be beneficial in endotoxaemia, but its antioxidant effect may be depend on dose, administration route and animal species. For this reason, when PTX is used in endotoxemia, treatment protocol should be done for each animal species.
Úãinek pentoxifyllinu na stav antioxidantÛ u zdrav˘ch a endotoxemick˘ch bíl˘ch novozélandsk˘ch králíkÛ V této studii byl zji‰Èován úãinek pentoxifyllinu na stav antioxidantÛ u zdrav˘ch a endotoxemick˘ch bíl˘ch novozélandsk˘ch králíkÛ. Endotoxemie byla vyvolána lipopolysacharidem E. coli. 40 králíkÛ bylo náhodnû rozdûleno do 4 stejn˘ch skupin. Skupina 1 slouÏila jako kontrolní. Skupinû 2 bylo aplikováno 400 µg·kg -1 lipopolysacharidu i.v. Skupinû 3 byl aplikován pentoxifyllin v dávce 50 mg·kg -1 intraperitoneálnû. Skupinû 4 byl aplikován zároveÀ pentoxifylin v dávce 50 mg·kg -1 intraperitoneálnû a lipopolysacharid v dávce 400 µg·kg -1 i.v. Zvífiata byla utracena 6 h po aplikaci a byly jim odebrány vzorky jater, srdce a ledvin. Bylo mûfieno mnoÏství malondialdehydu, superoxiddismutázy, glutathionperoxidázy v játrech, srdci a ledvinách. Ve srovnání s kontrolní skupinou zpÛsobil Lipopolysacharid statisticky v˘znamné zv˘‰ení jaterního malondialdehydu (p < 0,05), statisticky v˘znamn˘ vzrÛst aktivity glutathionperoxidázy v srdci, játrech a ledvinách (p < 0,05), nicménû zpÛsobil téÏ statisticky v˘znamné zv˘‰ení aktivity jaterní superoxiddismutázy (p < 0,05). Ve srovnání s kontrolní skupinou zpÛsobil pentoxifyllin satisticky v˘znamné (p < 0,05) zv˘‰ení koncentrace malondialdehydu, aktivity superoxiddismutázy v krvi a redukovaného glutathionu v játrech a ledvinách. Z v˘sledkÛ vypl˘vá, Ïe pentoxifylin nemá vyslovenû kladn˘ úãinek na stav antioxidantÛ u zdrav˘ch a endotoxemick˘ch bíl˘ch novozélandsk˘ch králíkÛ v podané dávce a zpÛsobu podání. I kdyÏ pentoxifyllin mÛÏe b˘t prospû‰n˘ pfii endotoxemii, jeho úãinek mÛÏe záviset na dávce, zpÛsobu podání a druhu zvífiete. Proto by se mûl pfii léãbû endotoxemií pentoxifyllinem vypracovat protokol léãby pro kaÏd˘ druh zvífiat zvlá‰È.
